Depot specificities of PPARγ ligand actions on lipid and glucose metabolism and their implication in PPAR-mediated body fat redistribution

Clinical Lipidology

Volumn 4, Issue 5, 2009, Pages 633-642

  Festuccia, William T ^a   Deshaies, Yves ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Adipose tissue remodeling; Apoptosis; Fat cell proliferation; Lipolysis; Preadipocyte differentiation; Rosiglitazone; Subcutaneous fat; Triacylglycerol synthesis; Visceral fat

Indexed keywords

FATTY ACID; GLITAZONE DERIVATIVE; GLYCEROPHOSPHATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL;

APOPTOSIS; BODY FAT DISTRIBUTION; BROWN ADIPOSE TISSUE; CELL DIFFERENTIATION; CELL METABOLISM; CELL PROLIFERATION; DYSLIPIDEMIA; FATTY ACID OXIDATION; FLUID RETENTION; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HEART FAILURE; HUMAN; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; LIPOGENESIS; LIPOLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT; SUBCUTANEOUS FAT; WEIGHT GAIN; WHITE ADIPOSE TISSUE;

RODENTIA;

EID: 77649124879     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.09.45     Document Type: Review

References (80)

1. Dreyer C, Krey G, Keller H et al.: Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68, 879-887 (1992).
2. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20, 649-688 (1999).
3. Zhu Y, Qi C, Korenberg JR et al.: Structural organization of mouse peroxisome proliferator-activated receptor γ(mPPAR γ) gene: alternative promoter use and different splicing yield two mPPAR γisoforms. Proc. Natl Acad. Sci. USA 92, 7921-7925 (1995).
4. Larsen TM, Toubro S, Astrup A: PPARγ agonists in the treatment of Type II diabetes: is increased fatness commensurate with long-term efficacy? Int. J. Obes. Relat. Metab. Disord. 27, 147-161 (2003).
5. Ferre P: The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53(Suppl. 1), S43-S50 (2004).
6. Bouaboula M, Hilairet S, Marchand J et al.: Anandamide induced PPARγ transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur. J. Pharmacol. 517, 174-181 (2005).
7. Beekum O, Fleskens V, Kalkhoven E: Posttranslational modifications of PPAR-γ: fine-tuning the metabolic master regulator. Obesity (Silver Spring) 17, 213-219 (2009).
8. Diradourian C, Girard J, Pegorier JP: Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87, 33-38 (2005).
9. Lonard DM, Lanz RB, O'Malley BW: Nuclear receptor coregulators and human disease. Endocr. Rev. 28, 575-587 (2007).
10. Lonard DM, O'Malley BW: Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol. Cell 27, 691-700 (2007).
11. Rochette-Egly C: Dynamic combinatorial networks in nuclear receptor-mediated transcription. J. Biol. Chem. 280, 32565-32568 (2005).
12. Feige JN, Auwerx J: Transcriptional coregulators in the control of energy homeostasis. Trends Cell. Biol. 17, 292-301 (2007).
13. Heikkinen S, Auwerx J, Argmann CA: PPARγin human and mouse physiology. Biochim. Biophys. Acta 1771, 999-1013 (2007).
14. Imai T, Takakuwa R, Marchand S et al.: Peroxisome proliferator-activated receptor γis required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl Acad. Sci. USA 101, 4543-4547 (2004).
15. Grimaldi PA: The roles of PPARs in adipocyte differentiation. Prog. Lipid Res. 40, 269-281 (2001).
16. Rosen ED, MacDougald OA: Adipocyte differentiation from the inside out. Nat. Rev. Mol. Cell Biol. 7, 885-896 (2006).
17. Tontonoz P, Spiegelman BM: Fat and beyond: the diverse biology of PPARγ. Annu. Rev. Biochem. 77, 289-312 (2008).
18. Agostini M, Schoenmakers E, Mitchell C et al.: Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell. Metab. 4, 303-311 (2006).
19. Barroso I, Gurnell M, Crowley VE et al.: Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402, 880-883 (1999).
20. Savage DB, Agostini M, Barroso I et al.: Digenic inheritance of severe insulin resistance in a human pedigree. Nat. Genet. 31, 379-384 (2002).
21. Rosen ED, Sarraf P, Troy AE et al.: PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4, 611-617 (1999).
22. Barak Y, Nelson MC, Ong ES et al.: PPAR 7gamma; is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585-595 (1999).
23. Kubota N, Terauchi Y, Miki H et al.: PPAR γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4, 597-609 (1999).
24. Medina-Gomez G, Gray SL, Yetukuri L et al.: PPAR γ2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 3, E64 (2007).
25. Lehmann JM, Moore LB, Smith-Oliver TA et al.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor γ(PPAR ?). J. Biol. Chem. 270, 12953-12956 (1995).
26. Semple RK, Chatterjee VK, O'Rahilly S: PPAR γand human metabolic disease. J. Clin. Invest. 116, 581-589 (2006).
27. Mudaliar S, Chang AR, Henry RR: Thiazolidinediones, peripheral edema, and Type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr. Pract. 9, 406-416 (2003).
28. Miyazaki Y, Mahankali A, Matsuda M et al.: Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. 87, 2784-2791 (2002).
29. Despres JP, Lemieux I: Abdominal obesity and metabolic syndrome. Nature 444, 881-887 (2006).
30. Yang X, Smith U: Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia 50, 1127-1139 (2007).
31. Wajchenberg BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr. Rev. 21, 697-738 (2000).
32. Kim JY, van de Wall E, Laplante M et al.: Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 117, 2621-2637 (2007).
33. Harman-Boehm I, Bluher M, Redel H et al.: Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J. Clin. Endocrinol. Metab. 92, 2240-2247 (2007).
34. Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ: The biology of white adipocyte proliferation. Obes. Rev. 2, 239-254 (2001).
35. Okuno A, Tamemoto H, Tobe K et al.: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101, 1354-1361 (1998).
36. de Souza CJ, Eckhardt M, Gagen K et al.: Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 50, 1863-1871 (2001).
37. Laplante M, Festuccia WT, Soucy G et al.: Mechanisms of the depot specificity of peroxisome proliferator-activated receptor γ action on adipose tissue metabolism. Diabetes 55, 2771-2778 (2006).
38. Yamauchi T, Kamon J, Waki H et al.: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor ? (PPAR?) deficiency and PPARγagonist improve insulin resistance. J. Biol. Chem. 276, 41245-41254 (2001).
39. Takamura T, Nohara E, Nagai Y, Kobayashi K: Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARγmRNA expression in 3T3-L1 adipocytes. Eur. J. Pharmacol. 422, 23-29 (2001).
40. Vernochet C, Milstone DS, Iehle C et al.: PPAR?-dependent and PPAR?-independent effects on the development of adipose cells from embryonic stem cells. FEBS Lett. 510, 94-98 (2002).
41. Niesler CU, Siddle K, Prins JB: Human preadipocytes display a depot-specific susceptibility to apoptosis. Diabetes 47, 1365-1368 (1998).
42. Adams M, Montague CT, Prins JB et al.: Activators of peroxisome proliferator-activated receptor γhave depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100, 3149-3153 (1997).
43. Kahn SE, Hull RL, Utzschneider KM: Mechanisms linking obesity to insulin resistance and Type 2 diabetes. Nature 444, 840-846 (2006).
44. Laplante M, Sell H, MacNaul KL, Richard D, Berger JP, Deshaies Y: PPAR-γ activation mediates adipose depot-specific effects on gene expression and lipoprotein lipase activity: mechanisms for modulation of postprandial lipemia and differential adipose accretion. Diabetes 52, 291-299 (2003).
45. Festuccia WT, Blanchard PG, Turcotte V et al.: Depot-specific effects of the PPARγ agonist rosiglitazone on adipose tissue glucose uptake and metabolism. J. Lipid Res. 50, 1185-1194 (2009).
46. Donkor J, Sariahmetoglu M, Dewald J, Brindley DN, Reue K: Three mammalian lipins act as phosphatidate phosphatases with distinct tissue expression patterns. J. Biol. Chem. 282, 3450-3457 (2007).
47. Yao-Borengasser A, Rasouli N, Varma V et al.: Lipin expression is attenuated in adipose tissue of insulin-resistant human subjects and increases with peroxisome proliferator-activated receptor γactivation. Diabetes 55, 2811-2818 (2006).
48. Reue K, Brindley DN: Thematic review series: glycerolipids. Multiple roles for lipins/ phosphatidate phosphatase enzymes in lipid metabolism. J. Lipid Res. 49, 2493-2503 (2008).
49. DiGirolamo M, Newby FD, Lovejoy J: Lactate production in adipose tissue: a regulated function with extra-adipose implications. FASEB J. 6, 2405-2412 (1992).
50. Anghel SI, Bedu E, Vivier CD et al.: Adipose tissue integrity as a prerequisite for systemic energy balance: a critical role for peroxisome proliferator-activated receptor γ. J. Biol. Chem. 282, 29946-29957 (2007).
51. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA: A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat. Med. 8, 1122-1128 (2002).
52. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM: PPAR γ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell Biol. 15, 351-357 (1995).
53. Festuccia WT, Laplante M, Berthiaume M, Gelinas Y, Deshaies Y: PPARγagonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control. Diabetologia 49, 2427-2436 (2006).
54. Kershaw EE, Schupp M, Guan HP et al.: PPARγregulates adipose triglyceride lipase in adipocytes in vitro and in vivo. Am. J. Physiol. Endocrinol. Metab. 293, E1736-E1745 (2007).
55. Oakes ND, Thalen PG, Jacinto SM, Ljung B: Thiazolidinediones increase plasma- adipose tissue FFA exchange capacity and enhance insulin-mediated control of systemic FFA availability. Diabetes 50, 1158-1165 (2001).
56. Koutsari C, Jensen MD: Thematic review series: Patient-oriented research. Free fatty acid metabolism in human obesity. J. Lipid Res. 47, 1643-1650 (2006).
57. Newsholme EA: Reflections on the mechanism of action of hormones. FEBS Lett. 117, K121-K134 (1980).
58. Brooks B, Arch JR, Newsholme EA: Effects of hormones on the rate of the triacylglycerol/ fatty acid substrate cycle in adipocytes and epididymal fat pads. FEBS Lett. 146, 327-330 (1982).
59. Kalderon B, Mayorek N, Ben-Yaacov L, Bar-Tana J: Adipose tissue sensitization to insulin induced by troglitazone and MEDICA 16 in obese Zucker rats in vivo. Am. J. Physiol. Endocrinol. Metab. 284, E795-E803 (2003).
60. Miyoshi H, Shulman GI, Peters EJ, Wolfe MH, Elahi D, Wolfe RR: Hormonal control of substrate cycling in humans. J. Clin. Invest. 81, 1545-1555 (1988).
61. Wolfe RR, Klein S, Carraro F, Weber JM: Role of triglyceride-fatty acid cycle in controlling fat metabolism in humans during and after exercise. Am. J. Physiol. 258, E382-E389 (1990).
62. Frayn KN, Langin D, Karpe F: Fatty acid-induced mitochondrial uncoupling in adipocytes is not a promising target for treatment of insulin resistance unless adipocyte oxidative capacity is increased. Diabetologia 51, 394-397 (2008).
63. Harper RD, Saggerson ED: Factors affecting fatty acid oxidation in fat cells isolated from rat white adipose tissue. J. Lipid Res. 17, 516-526 (1976).
64. Wilson-Fritch L, Nicoloro S, Chouinard M et al.: Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J. Clin. Invest. 114, 1281-1289 (2004).
65. Boden G, Homko C, Mozzoli M, Showe LC, Nichols C, Cheung P: Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 54, 880-885 (2005).
66. Bogacka I, Xie H, Bray GA, Smith SR: Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54, 1392-1399 (2005).
67. Cannon B, Nedergaard J: Brown adipose tissue: function and physiological significance. Physiol. Rev. 84, 277-359 (2004).
68. Cypess AM, Lehman S, Williams G et al.: Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 360, 1509-1517 (2009).
69. Rothwell NJ, Stock MJ: Biological distribution and significance of brown adipose tissue. Comp. Biochem. Physiol. A Comp. Physiol. 82, 745-751 (1985).
70. Petrovic N, Shabalina IG, Timmons JA, Cannon B, Nedergaard J: Thermogenically competent nonadrenergic recruitment in brown preadipocytes by a PPARγagonist. Am. J. Physiol. Endocrinol. Metab. 295, E287-E296 (2008).
71. Festuccia WT, Blanchard PG, Turcotte V et al.: The PPARγagonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake. Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R1327-R1335 (2009).
72. Laplante M, Festuccia WT, Soucy G et al.: Involvement of adipose tissues in the early hypolipidemic action of PPARγagonism in the rat. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292, R1408-R1417 (2007).
73. Sell H, Berger JP, Samson P et al.: Peroxisome proliferator-activated receptor γ agonism increases the capacity for sympathetically mediated thermogenesis in lean and ob/ob mice. Endocrinology 145, 3925-3934 (2004).
74. Festuccia WT, Oztezcan S, Laplante M et al.: Peroxisome proliferator-activated receptor-γ-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 149, 2121-2130 (2008).
75. Yanase T, Yashiro T, Takitani K et al.: Differential expression of PPAR γ1 and γ2 isoforms in human adipose tissue. Biochem. Biophys. Res. Commun. 233, 320-324 (1997).
76. Lefebvre AM, Laville M, Vega N et al.: Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 47, 98-103 (1998).
77. Montague CT, Prins JB, Sanders L et al.: Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47, 1384-1391 (1998).
78. Picard F, Gehin M, Annicotte J et al.: SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111, 931-941 (2002).
79. Leonardsson G, Steel JH, Christian M et al.: Nuclear receptor corepressor RIP140 regulates fat accumulation. Proc. Natl Acad. Sci. USA 101, 8437-8442 (2004).
80. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116, 1784-1792 (2006).